We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Orexo's "Out the Monster" campaign wins a Gold Lions Health Award at the Cannes Lions Festival PR Newswire MORRISTOWN, N.J., June 25, 2015 MORRISTOWN, N.J., June 25, 2015 /PRNewswire/...
Orexo US launches new 8.6/2.1 mg ZUBSOLV® (buprenorphine/naloxone) sublingual tablet CIII: 8.6/2.1mg Offers additional option for physicians and patients to tailor maintenance treatment of opioid...
Orexo Features Positive Results from the ISTART Study at the 2014 AAAP Meeting Data presented from largest combination buprenorphine/naloxone opioid dependence trial ever conducted in the U.S. PR...
Orexo Launches ZUBSOLV Patient Assistance Program Helping eligible opioid dependent patients in need PR Newswire MORRISTOWN, N.J., Oct. 7, 2014 MORRISTOWN, N.J., Oct. 7, 2014 /PRNewswire/ -- As...
Thu, Nov 21, 2013 - Orexo AB (ORXOY: OTCQX International) released a Company Presentation called Jefferies Global Healthcare Conf. 2013. To watch the presentation, please visit:...
Orexo AB Begins Trading on OTCQX® PR Newswire NEW YORK, Nov. 13, 2013 NEW YORK, Nov. 13, 2013 /PRNewswire/ --OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected...
/C O R R E C T I O N -- Orexo U.S./ PR Newswire NEW YORK, Sept. 16, 2013 In the news release, Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence, issued...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 1.885 | 1.885 | 1.885 | 250 | 1.885 | DR |
12 | 0.335 | 21.6129032258 | 1.55 | 1.885 | 0.889 | 333 | 1.20635 | DR |
26 | -0.265 | -12.3255813953 | 2.15 | 2.22 | 0.889 | 510 | 1.63651786 | DR |
52 | 0.285 | 17.8125 | 1.6 | 2.35 | 0.889 | 583 | 1.72773881 | DR |
156 | -0.882 | -31.8756776292 | 2.767 | 2.82 | 0.76 | 816 | 1.75367041 | DR |
260 | -4.715 | -71.4393939394 | 6.6 | 9 | 0.76 | 711 | 2.81780011 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions